Page 10 - Aurobindo Pharma

Aurobindo Pharma hits 52-week low, slips 25% in one month

The stock of the pharmaceutical company was trading at its lowest level since June 2020

Near term upsides for Aurobindo Pharma stock capped on weak US outlook

The company has been making small acquisitions to bridge the growth gap

Aurobindo Pharma dips 5% on weak operational performance in June quarter

Aurobindo Pharma has entered into definitive agreements under which the Company will subscribe to fresh equity shares in Cronus amounting to Rs 420 crore

Aurobindo Pharma Q1 consolidated net profit declines 2% to Rs 770 crore

Aurobindo Pharma on Thursday reported a 1.68 per cent decline in its consolidated net profit to Rs 769.97 crore for the quarter ended on June 30, 2021, mainly on account of reduction in expenses

Aurobindo Pharma channelising efforts to commercialise Covid-19 vaccine

The Hyderabad-based drug major is looking to develop products with higher complexity, focus on injectables business and expand business in high growth markets like China.

Injectables consolidation could fetch higher valuations for Aurobindo

Separate listing could capture strong growth rates which is not the case in the current structure

Aurobindo Pharma to transfer biz in Unit-4 to arm Eugia Pharma; stock up 4%

The company said the transfer of the business undertaking will be done for a lumpsum consideration of Rs 876 crore

Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on

MSTC's stock has been in a consolidation phase for quite some time maintaining the base near 255 levels and currently has given a bullish candle pattern in the daily chart

Nifty Pharma index hits new high; Aurobindo, Dr Reddy's gain over 3%

Marksans Pharma and Novartis India from the S&P BSE Healthcare index zoomed 20 per cent each

Lack of near-term triggers to cap upsides in Aurobindo Pharma

Upsides from capex and investments across segments are at least three years away

Stocks to watch: HDFC Bank, M&M, BoB, Affle (India), Aurobindo Pharma, PNB

Bank of Baroda (BoB) reported a standalone net loss of Rs 1,047 crore in the quarter ended March 2021, as it shifted to a new tax regime

Strong injectables portfolio to support Aurobindo Pharma's growth

The stock has been underperforming recent months and trades at a discount to peers

Aurobindo Pharma steady as analysts watch numbers for near-term growth

The company's investments across segments will take at least two years to play out, say analysts

Aurobindo Pharma Q3 net profit zooms over four-fold to Rs 2,946.32 cr

Aurobindo Pharma reported an over four-fold jump in its consolidated net profit to Rs 2,946.32 crore for the quarter ended December 31, 2020 mainly on account of one time exceptional gains.

Aurobindo gains 5% on govt nod for promotion of manufacturing bulk drugs

Aurobindo Pharma (through Lyfius Pharma) has received government approval for setting up plants for production of Penicillin-G and 7-ACA, under the PLI scheme

Aurobindo Pharma, KAPL get nod for promotion of manufacturing bulk drugs

The government has given approval to drug firms includingAurobindo Pharma and Karnataka Antibiotics & Pharmaceuticals under the PLI scheme for promotion of domestic manufacturing of critical bulk drugs. The Production Linked Incentive (PLI) scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country. The setting up of plants under the scheme will lead to total committed investment of Rs 3,761 crore by the companies and employment generation for around 3,825 people,the Ministry of Chemicals and Fertilizers said in a statement. The applications of Aurobindo Pharma (through Lyfius Pharma) have been approved for setting up plants for the production ofPenicillin G, and 7-ACA, with committed production capacity of15,000 MT and2,000 MT, respectively. The committed investment for Penicillin G is Rs1,392 crore, and for 7-ACA isRs 813 crore, it added. The approval has also been given to Aurobindo Pharma (through Qule Pharma)

Pharma, healthcare growing, but they face challenges beyond Covid-19

These sectors will face another tough year after coronavirus pandemic, the first challenge being vaccination of India's 1.3 billion people. Devangshu Datta explains the opportunities and threats

India Coronavirus Dispatch: Nod to Covaxin raises many eyebrows

Other vaccines being developed in India, dangerous conspiracy theories, private hospitals keen on jumping in-news relevant to India's fight against Covid-19

Here's a Bull Spread Strategy on Aurobindo Pharma by HDFC Securities

The stock price has broken out from the downward slopping trendline

Aurobindo Pharma joins hands with Covaxx for coronavirus vaccine

According to a release issued by the drug maker, Covaxx is currently conducting a Phase 1 clinical trial for the vaccine candidate